During the last session, Novo Nordisk ADR (NYSE:NVO)’s traded shares were 14.06 million, with the beta value of the company hitting 0.65. At the end of the trading day, the stock’s price was $67.55, reflecting an intraday gain of 1.90% or $1.26. The 52-week high for the NVO share is $148.15, that puts it down -119.32 from that peak though still a striking 15.62% gain since the share price plummeted to a 52-week low of $57.00. The company’s market capitalization is $227.25B, and the average trade volume was 8.93 million shares over the past three months.
Novo Nordisk ADR (NVO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.03. NVO has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
Novo Nordisk ADR (NYSE:NVO) trade information
Novo Nordisk ADR (NVO) registered a 1.90% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.90% in intraday trading to $67.55, hitting a weekly high. The stock’s 5-day price performance is 1.66%, and it has moved by 6.14% in 30 days. Based on these gigs, the overall price performance for the year is -45.10%.
The consensus price target of analysts on Wall Street is $158, which implies an increase of 57.25% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $156 and $160 respectively. As a result, NVO is trading at a discount of -136.86% off the target high and -130.94% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.74%. While earnings are projected to return 25.59% in 2025, the next five years will return 19.47% per annum.
NVO Dividends
Novo Nordisk ADR is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Novo Nordisk ADR is 1.66, with the dividend yield indicating at 2.46 percent, continuing the trend of increasing dividends in recent years.
The next largest institutional holding, with 19.49 million shares, is of FMR LLC’s that is approximately 0.4373% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.78 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Novo Nordisk ADR (NVO) shares are Goldman Sachs TRT II-Goldman Sachs GQG Part. Intl Opportunities Fd. and HARBOR FUNDS-Harbor Capital Appreciation Fund . Data provided on Jan 31, 2025 indicates that Goldman Sachs TRT II-Goldman Sachs GQG Part. Intl Opportunities Fd. owns about 4.82 shares. This amounts to just over 0.14 percent of the company’s overall shares, with a $325.68 million market value. The same data shows that the other fund manager holds slightly less at 4.22, or about 0.12% of the stock, which is worth about $285.01 million.
